The innate immune response to tumors and its role in the induction of T-cell immunity

Immunological Reviews

Volumn 188, Issue , 2002, Pages 9-21

  Diefenbach, Andreas ^a   Raulet, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GAMMA INTERFERON RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETINOIC ACID; STAT1 PROTEIN; TRANSCRIPTION FACTOR; UL16 BINDING PROTEIN; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; NATURAL KILLER CELL ACTIVATING RECEPTORS; TUMOR ANTIGEN;

ARTICLE; GENETIC ANALYSIS; HUMAN; IMMUNE RESPONSE; LIGAND BINDING; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; GRAFT REJECTION; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MOUSE; MOUSE MUTANT; NEOPLASM; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOCOMPETENCE; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SELF TOLERANCE; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS;

EID: 0036812626     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18802.x     Document Type: Article

References (110)

1. Burnet FM. Immunological aspects of malignant disease. Lancet 1967;1:1171-1174.
2. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971;28:89-98.
3. McClain KL. Immunodeficiency states and related malignancies. Cancer Treat Res 1997;92:39-61.
4. Smyth M, Godfrey D, Trapani J. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-299.
5. Ljunggren H-G, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. J Exp Med 1985;162:1745-1759.
6. Seaman W, Sleisenger M, Eriksson E, Koo G. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 1987;138:4539-4544.
7. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000;97:2731-2736.
8. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and H60 ligands of the HKG2D receptor stimulate tumour immunity. Nature 2001;413:165-171.
9. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618.
10. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations, the role of MHC class I expression. J Exp Med 1994;179:1215-1224.
11. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-1421.
12. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-366.
13. d cytolytic T cells. Cell 1989;58:293-303.
14. van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
15. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
16. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: Lessons learned from melanoma. Curr Opin Immunol 2001;13:134-140.
17. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974;183:534-536.
18. Stutman O. Chemical carcinogenesis in nude mice: Comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 1979;62:353-358.
19. Stutman O. Spontaneous tumors in nude mice: Effect of the viable yellow gene. Exp Cell Biol 1979;47:129-135.
20. Gillis S, Union NA, Baker PE, Smith KA. The in vitro generation and sustained culture of nude mouse cytolytic T lymphocytes. J Exp Med 1979;149:1460-1476.
21. Hunig T, Bevan MJ. Ability of nude mice to generate alloreactive, xenoreactive and H-2-restricted cytotoxic T-lymphocyte responses. Exp Cell Biol 1984;52:7-11.
22. Kaplan DH, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
23. Shankaran V, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
24. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16:216-229.
25. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975;16:230-239.
26. Karre K, Klein GO, Kiessling R, Klein G, Roder JC. Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature 1980:284:624-626.
27. Karre K, Klein GO, Kiessling R, Klein G, Roder JC. In vitro NK-activity and in vivo resistance to leukemia: Studies of beige, beige//nude and wild-type hosts on C57BL background. Int J Cancer 1980;26:789-797.
28. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980;284:622-624.
29. van den Broek M, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-1790.
30. Smyth MJ, Thia KYT, Street SEA, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-760.
31. Takeda K, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
32. Smyth MJ, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-670.
33. Takeda K, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-169.
34. Piontek GE, et al. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol 1985;135:4281-4288.
35. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986;319:675-678.
36. Ljunggren H-G, Sturmhöfel K, Wolpert E, Hämmerling GJ, Karre K. Transfection of β2-microglobulin restores IFN-mediated protection from natural killer cell lysis in Yac-1 lymphoma variants. J Immunol 1990;145:380-386.
37. Franksson L, George E, Powis S, Butcher G, Howard J, Karre K. Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex encoded transporter gene. J Exp Med 1993;177:201-205.
38. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995;67:155-195.
39. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
40. Yokoyama WM, Jacobs LB, Kanagawa O, Shevach EM, Cohen DI. A murine T lymphocyte antigen belongs to a supergene family of type II integral membrane proteins. J Immunol 1989;143:1379-1386.
41. Chan PY, Takei F. Molecular cloning and characterization of a novel murine T cell surface antigen, YE1/48. J Immunol 1989;142:1727-1736.
42. + IL-2 activated natural killer cells. Nature 1992;358:66-70.
43. Moretta A, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specifities. J Exp Med 1993;178:597-604.
44. Wagtmann N, et al. Molecular clones of the p58 natural killer cell receptor reveal Ig-related molecules with diversity in both the extra- and intra-cellular domains. Immunity 1995;2:439-449.
45. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 1995;3:801-809.
46. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268:405-408.
47. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173:1017-1020.
48. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol 1996;157:4741-4745.
49. Carretero M, et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol 1997;27:563-567.
50. Vance RE, Tanamachi DM, Hanke T, Raulet DH. Cloning of a mouse homolog of CD94 extends the family of C-type lectins on murine natural killer cells. Eur J Immunol 1997;27:3236-3241.
51. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. Nature 1998;391:795-799.
52. b. J Exp Med 1998;188:1841-1848.
53. Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J Exp Med 1999;190:1801-1812.
54. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001;19:291-330.
55. Bix M, Liao N-S, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient hemopoietic cells by irradiated MHC-matched mice. Nature 1991;349:329-331.
56. Kusunoki Y, et al. NK-mediated elimination of mutant lymphocytes that have lost expression of MHC class I molecules. J Immunol 2000;165:3555-3563.
57. Langlois RG, et al. Evidence for increased somatic cell mutations at the glycophorin A locus in atomic bomb survivors. Science 1987;236:445-448.
58. Jensen RH, et al. Elevated frequency of glycophorin A mutations in erythrocytes from Chernobyl accident victims. Radiat Res 1995;141:129-135.
59. Kushiro J, et al. Development of a flow-cytometric HLA-A locus mutation assay for human peripheral blood lymphocytes. Mutat Res 1992;272:17-29.
60. Leiden J, Karpinski B, Gottschalk L, Kornbluth J. Susceptibility to natural killer cell mediated cytolysis is independent of the level of target cell class I HLA expression. I Immunol 1989;142:2140-2147.
61. b antigen expression has no effect on natural killer susceptibility and tumoregenicity of a murine hepatoma. J Immunol 1988;141:4403-4409.
62. Pena J, Alonso C, Solana R, Serrano R, Carracedo J, Ramirez R. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol 1990;20:2445-2448.
63. Litwin V, Gumperz J, Parham P, Phillips J, Lanier L. Specificity of HLA class I antigen recognition by human NK clones: Evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J Exp Med 1993;178:1321-1336.
64. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001;181:170-184.
65. Moretta L, et al. Activating receptors and co-receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
66. Ryan J, Niemi E, Nakamura M, Seaman W. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J Exp Med 1995;181:1911-1915.
67. Ho EL, Heusel JW, Brown MG, Matsumoto K, Scalzo AA, Yokoyama WM. Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci USA 1998;95:6320-6325.
68. Berg SF, Dissen E, Westgaard IH, Fossum S. Molecular characterization of rat NKR-P2, a lectin-like receptor expressed by NK cells and resting T cells. Int Immunol 1998;10:379-385.
69. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-126.
70. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
71. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
72. Pende D, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31:1076-1086.
73. Wu J, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-732.
74. Chang C, et al. KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J Immunol 1999;163:4652-4654.
75. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 2000;192:1059-1067.
76. Songyang Z, et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993;72:767-778.
77. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-679.
78. Jiang K, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000;1:419-425.
79. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1:41-49.
80. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8 αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2:255-260.
81. Roberts AI, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001;167:5527-5530.
82. Diefenbach A, et al. Stimulatory and co-stimulatory functions of the immunoreceptor NKG2D are determined by selective usage of signaling adaptor molecules. Nat Immunol 2002; in press.
83. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994;91:6259-6263.
84. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996;93:12445-12450.
85. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:1737-1740.
86. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
87. Cerwenka A, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-727.
88. Nomura M, Zou Z, Joh T, Takihara Y, Matsuda Y, Shimada K. Genomic structures and characterization of Rael family members encoding GPI-anchored cell surface proteins and expressed predominantly in embryonic mouse brain. J Biochem 1996;120:987-995.
89. Zou Z, Nomura M, Takihara Y, Yasunaga T, Shimada K. Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: A novel cDNA family encodes cell surface proteins sharing partial homology with MHC class I molecules. J Biochem 1996;119:319-328.
90. Girardi M, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294:605-609.
91. Carayannopoulos LN, Naidenko OV, Kinder J, Ho EL, Fremont DH, Yokoyama WM. Ligands for murine NKG2D display heterogeneous binding behavior. Eur J Immunol 2002;32:597-605.
92. Malarkannan S, et al. The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol 1998;161:3501-3509.
93. Cosman D, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
94. Onda H, et al. A novel secreted tumor antigen with a glycosylphosphatidylinositol-anchored structure ubiquitously expressed in human cancers. Biochem Biophys Res Commun 2001;285:235-243.
95. Radosavljevic M, et al. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-Q25.3. Genomics 2002;79:114-123.
96. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001;98:11521-11526.
97. Sivori S, et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997;186:1129-1136.
98. Cantoni C, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-796.
99. Pende D, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-1516.
100. Pessino A, et al. Molecular cloning of NKp46: A novel member of the imununo-globulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998;188:953-960.
101. Vitale M, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-2072.
102. Goodwin RG, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993;73:447-456.
103. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998;10:491-499.
104. Takeda K, et al. CD27-mediated activation of murine NK cells. J Immunol 2000;164:1741-1745.
105. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000;1:433-440.
106. Herbst H, Raff T, Stein H. Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol 1996;179:54-59.
107. Wolthers KC, et al. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: Regulation by CD4+ T cells. Eur J Immunol 1996;26:1700-1706.
108. Kelly JM, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002;3:83-90.
109. Liao N, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: Susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
110. - bone marrow in chimeric mice. Proc Natl Acad Sci USA 1991;88:10332-10336.